NCT05334576View on ClinicalTrials.gov

Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA

NAUnknownINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2025

Conditions

Sickle Cell Disease

Interventions

OTHER

Crizanlizumab

Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months

Trial Locations (1)

63110

RECRUITING

Barnes-Jewish Hospital, St Louis

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Andria Ford

OTHER